检索结果-南通市图书馆

EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from “ERBITUX-OUEST”

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Internal Medicine 2016年第2期6卷 56-67页

作者： Jean-Philippe Metges Erick Gamelin Alain Volant Olivier Capitain Jean-François Ramée Jean-Luc Raoul Jean-Yves Douillard Pierre-Luc Etienne Isabelle Cumin Olivier Dupuis Roger Faroux Marie-Aude Coulon Philippe Deguiral Karine Bideau Nacr Eddine Achour Alain Gourlaouen Corinne Alleaume Annie Wdowik Laurent Miglianico Yann Touchefeu Vincent Klein Alain Penchet Ludovic Rosenfeld Daniel Martin Claire Stampfli Jean-Jacques Auger Alain Bargain Murielle Broyer-Petit Jérome Chettrit Louis-Rémi De Ybarlucea Serge Eloit Pierre Marie Girardot Nathalie Heresbach Christian Laboisse Eric Lavoine gilles Lemasson Claire Magois Sophie Michalak Norbert Padilla Joseph Politis Frédéric Staroz Bruno Turlin Arnaud Uguen Viorel Vasiliu Véronique Verriele Fanny Marhuenda Delphine Déniel Lagadec Christian Riché Françoise Grudé Observatoire dédié au Cancer des régions Bretagne et Pays de la Loire France Centre Hospitalier Régional Universitaire (CHRU) Brest France Institut de Cancérologie de l’Ouest (ICO) Paul Papin Angers France Centre Catherine de Sienne Nantes France CRLCC Eugène Marquis Rennes France ICO René Gauducheau Nantes France Centre CARIO-HCPA Plérin France Centre Hospitalier Bretagne Sud (CHBS) Lorient France Clinique Victor Hugo Le Mans France Centre Hospitalier Départemental (CHD) La Roche-sur-Yon France CH Le Mans France Clinique Mutualiste de l’Estuaire Saint-Nazaire France CHIC Quimper France Clinique Pasteur Lanroze Brest France CH MORLAIX France CH Saint-Brieuc France CHBA Vannes France CHP Saint-Grégoire France CHU Nantes France Hopital Privé Océane Vannes France Clinique Saint-Michel et Sainte-Anne Quimper France Pole Santé Sarthe et Loire La Flèche France Polyclinique du Maine Laval France Polyclinique Sud Quimper France CH Laval France Polyclinique Cesson Sévigné France Laboratoire d’anatomie et de cytologie pathologiques Cholet France Cabinet d’anatomie et de cytologie pathologiques Saint-Malo France Laboratoire d’anatomie et de cytologie pathologiques Lorient France Institut d’histopathologie Nantes France Laboratoire de Pathologie Médicale Laval France ARMOR Pathologie Plérin France Laboratoire d’anatomie et de cytologie pathologiques Rennes France Laboratoire d’anatomie et de cytologie pathologiques Angers France Laboratoire Analyses Biologie Glasgow Brest France CHU Angers France Centre d’anatomie et de cytologie pathologiques Le Mans France Cabinet d’anatomie et de cytologie pathologiques Vannes France Laboratoire d’anatomie et de cytologie pathologiques Quimper France CHU Rennes France

Purpose: Although controversial, assessment of epidermal growth factor receptor (EGFR) expression is required for the approved indications of Cetuximab in metastatic colorectal cancer (mCRC). With the objective of improving patient selection, “ERBITUX-OUEST” study aimed at analyzing EGFR status in a large cohort of mCRC patients who received cetuximab without preliminary EGFR screening, and assessing the correlation between EGFR status and response to treatment retrospectively. Patients and methods: 332 patients treated with Irinotecan Cetuximab based regimen after progression on irinotecan or oxaliplatin therapy were included. EGFR status was assessed using three available immunohistochemistry (IHC) tests and in situ hybridization in case of negativity. Clinical outcomes of EGFR-positive and EGFR-non-detected (or considered as negative with at least one test) patients were compared. Results: Of the 332 samples centrally screened, 194 were classified as full-positive (i.e., EGFR-positive for all three tests), 86 as full-negative, and 52 as discordant. One third of the 131 negative samples with FDA approved test should be reclassified as positive with at least one of the two others tests. Regarding results from FDA approved test only, neither objective response rate (ORR), progression-free survival (PFS) nor overall survival (OS) differed significantly between EGFR-negative and EGFR-positive patients (P = 0.788, 0.326 and 0.888, respectively). Similarly, comparison of full-negative to other groups did not show any significant difference in terms of ORR (P = 0.507), PFS (P = 0.222) or OS (P = 0.686). Conclusion: These data strongly argue against mCRC patients selection for Cetuximab treatment based on EGFR expression as measured by currently available IHC technics.

关键词： Metastatic Colorectal Cancer Cetuximab EGFR Expression

肝脏切除术治疗非结直肠癌、非内分泌肿瘤来源的转移性肝癌：1452例患者的资料分析和预后模型的建立

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

医学信息（手术学分册） 2007年第9期20卷 802-802页

作者： Adam, Rene Chiche, Laurence Aloia, Thomas Elias, Dominique Salmon, Remy Rivoire, Michel Jaeck, Daniel Saric, Jean Le Treut,Yves Patrice Belghiti, Jacques Mantion, Georges Mentha, gilles the Association Francaise de Chirurgie

研究目的：明确肝脏切除术（HR）在非结直肠、非内分泌肿瘤来源的转移性肝癌（NCNELM）患者中的治疗作用。背景资料总结：HR在NCNELM患者中的治疗地位仍有争议，主要原因在于先前发表的报道有限，同时肿瘤原发部位与组织学存在异质性。... 详细信息

研究目的：明确肝脏切除术（HR）在非结直肠、非内分泌肿瘤来源的转移性肝癌（NCNELM）患者中的治疗作用。背景资料总结：HR在NCNELM患者中的治疗地位仍有争议，主要原因在于先前发表的报道有限，同时肿瘤原发部位与组织学存在异质性。方法：在1983—2004年间，对1452例接受HR的NCNELM患者进行预后因素和长期疗效分析，在此基础上建立多变量风险模型。研究结果：56％患者为肝脏孤立转移灶；71％为单侧（平均直径50．5mm）。

关键词：非内分泌肿瘤肝脏切除术转移性肝癌治疗作用结直肠癌预后模型原发部位疗效分析

非ST段抬高急性冠脉综合征患者噻吩并吡啶类药物预治疗的再评价：一项系统性综述和meta分析

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

英国医学杂志中文版 2015年第3期18卷 129-129页

作者： Anne BeUemain-Appaix Mathieu Kerneis Stephen A O'Connor Johanne Silvain Michel Cucherat Farzin Beygui Olivier Barthelemy Jean-Philippe Collet Laurent Jacq Francois Bernasconi gilles Montalescot 葛兴史旭波 Service deCardiologie-LaFontonne Hospital Antibes France Institut deCardiologie INSERMUMRS1166 Pitie Salpetrie Hospital( AP-HP ) Universite Paris 6 France ACTION StudyGroup Paris France UMR CNRS 5558 Universite Lyon I Laennec LyonFrance 首都医科大学附属北京同仁医院心血管中心

目的探讨非sT段抬高急性冠脉综合征患者应用P2Y12受体拮抗剂预治疗与未行预治疗相比的有效性和安全性。数据来源两名研究者独立检索Medline、Embase、Cochrane Controlled Trials和BioMed Central数据库，查找2001年至2014年随机对照试... 详细信息

目的探讨非sT段抬高急性冠脉综合征患者应用P2Y12受体拮抗剂预治疗与未行预治疗相比的有效性和安全性。数据来源两名研究者独立检索Medline、Embase、Cochrane Controlled Trials和BioMed Central数据库，查找2001年至2014年随机对照试验和观察性研究。入选标准研究必须报告全因病死率（主要疗效终点）和大出血事件（安全性终点）结局。数据提取独立提取和分析有关样本量、人群特征、药物剂量、服药延迟情况和临床预后信息的数据。

关键词：急性冠脉综合征预处理系统吡啶噻吩 ST 患者评估

沃尔巴克氏菌(Wolbachia)结合放射线的应用现场清除白纹伊蚊种群

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中华实验和临床病毒学杂志 2019年第5期33卷 494-494页

作者： Xiaoying Zheng Dongjing Zhang Yongjun Li Cui Yang Yu Wu Xiao Liang Yongkang Liang Xiaoling Pan Linchao Hu Qiang Sun Xiaohua Wang Yingyang Wei Jian Zhu Wei Qian Ziqiang Yan Andrew GParker jeremie r.l.gilles Kostas Bourtzis Jeremy Bouyer Moxun tang Bo Zheng Jianshe Yu Julian Liu Jiajia Zhuang Zhigang Hu Meichun Zhang Juntao Gong Xiaoyue Hong Zhoubing Zhang Lifeng Lin Qiyong Liu Zhiyong Hu Zhongdao Wu Luke Anthony Baton Ary AHoffmann Zhiyong Xi 毛伟(编译) 曾琴(编译) 潘晓玲(编译) 梁国栋(审校) 不详湖南师范大学医学院湖南长沙410013

《自然》杂志近期发表论文介绍中国、美国、国际原子能机构和澳大利亚科学家通过合作于2014—2017年在中国广东省广州市南沙区和番禺区2个江中沙洲岛屿,开展清除白纹伊蚊即登革病毒主要传播蚊虫的现场研究。该研究结合昆虫绝育技术(ster... 详细信息

《自然》杂志近期发表论文介绍中国、美国、国际原子能机构和澳大利亚科学家通过合作于2014—2017年在中国广东省广州市南沙区和番禺区2个江中沙洲岛屿,开展清除白纹伊蚊即登革病毒主要传播蚊虫的现场研究。该研究结合昆虫绝育技术(sterile insect technique,SIT),通过释放携带沃尔巴克氏菌(Wolbachia)的白纹伊蚊雄蚊,而达到靶向消灭现场野生白纹伊蚊的目的。研究结果显示,此项技术可年平均消灭现场白纹伊蚊83%~94%雌性成蚊和94%蚊卵,在部分区域实现了野生白纹伊蚊种群的灭绝。

关键词：白纹伊蚊国际原子能机构登革病毒放射线沃尔巴克应用现场 Wolbachia

Performance and calibration of quark/gluon-jet taggers using 140 fb^(-1) of pp collisions at √s=13 TeV with the ATLAS detector

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Physics C 2024年第2期48卷 1-25页

作者： G. Aad B. Abbott K. Abeling N.J. Abicht S.H. Abidi A. Aboulhorma H. Abramowicz H. Abreu Y. Abulaiti B.S. Acharya C. Adam Bourdarios L. Adamczyk S.V. Addepalli M.J. Addison J. Adelman A. Adiguzel T. Adye A.A. Affolder Y. Afik M.N. Agaras J. Agarwala A. Aggarwal C. Agheorghiesei A. Ahmad F. Ahmadov W.S. Ahmed S. Ahuja X. Ai G. Aielli A. Aikot M. Ait Tamlihat B. Aitbenchikh I. Aizenberg M. Akbiyik T.P.A. Åkesson A.V. Akimov D. Akiyama N.N. Akolkar K. Al Khoury G.L. Alberghi J. Albert P. Albicocco G.L. Albouy S. Alderweireldt M. Aleksa I.N. Aleksandrov C. Alexa T. Alexopoulos F. Alfonsi M. Algren M. Alhroob B. Ali H.M.J. Ali S. Ali S.W. Alibocus M. Aliev G. Alimonti W. Alkakhi C. Allaire B.M.M. Allbrooke J.F. Allen C.A. Allendes Flores P.P. Allport A. Aloisio F. Alonso C. Alpigiani M. Alvarez Estevez A. Alvarez Fernandez M. Alves Cardoso M.G. Alviggi M. Aly Y. Amaral Coutinho A. Ambler C. Amelung M. Amerl C.G. Ames D. Amidei S.P. Amor Dos Santos K.R. Amos V. Ananiev C. Anastopoulos T. Andeen J.K. Anders S.Y. Andrean A. Andreazza S. Angelidakis A. Angerami A.V. Anisenkov A. Annovi C. Antel M.T. Anthony E. Antipov M. Antonelli F. Anulli M. Aoki T. Aoki J.A. Aparisi Pozo M.A. Aparo L. Aperio Bella C. Appelt A. Apyan N. Aranzabal S.J. Arbiol Val C. Arcangeletti A.T.H. Arce E. Arena J-F. Arguin S. Argyropoulos J.-H. Arling O. Arnaez H. Arnold G. Artoni H. Asada K. Asai S. Asai N.A. Asbah J. Assahsah K. Assamagan R. Astalos S. Atashi R.J. Atkin M. Atkinson H. Atmani P.A. Atmasiddha K. Augsten S. Auricchio A.D. Auriol V.A. Austrup G. Avolio K. Axiotis G. Azuelos D. Babal H. Bachacou K. Bachas A. Bachiu F. Backman A. Badea P. Bagnaia M. Bahmani A.J. Bailey V.R. Bailey J.T. Baines L. Baines O.K. Baker E. Bakos D. Bakshi Gupta V. Balakrishnan R. Balasubramanian E.M. Baldin P. Balek E. Ballabene F. Balli L.M. Baltes W.K. Balunas J. Balz E. Banas M. Bandieramonte A. Bandyopadhyay S. Bansal L. Barak M. Barakat E.L. Barberio D. Barberis M. Barbero M.Z. Barel K.N. Barends T. Barillari M-S. Barisits T. Barklow P. Baron D.A. Baron Mo The ATLAS Collaboration

The identification of jets originating from quarks and gluons,often referred to as quark/gluon tagging,plays an important role in various analyses performed at the Large Hadron Collider,as Standard Model measurements and searches for new particles decaying to quarks often rely on suppressing a large gluon-induced *** paper describes the measurement of the efficiencies of quark/gluon taggers developed within the ATLAS Collaboration,using √s=13 TeV proton–proton collision data with an integrated luminosity of 140 fb^(-1) collected by the ATLAS *** taggers with high performances in rejecting jets from gluon over jets from quarks are studied:one tagger is based on requirements on the number of inner-detector tracks associated with the jet,and the other combines several jet substructure observables using a boosted decision tree.A method is established to determine the quark/gluon fraction in data,by using quark/gluon-enriched subsamples defined by the jet *** in tagging efficiency between data and simulation are provided for jets with transverse momentum between 500 GeV and 2 TeV and for multiple tagger working points.

关键词： ATLAS JET QUARK GLUON TAGGING